A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/Refractory Acute Myeloid Leukemia (AML)

被引：0

作者：

Advani, Anjali S. ^{[1
]}

Cooper, Brenda ^{[2
]}

Elson, Paul ^{[3
]}

Mukherjee, Sudipto ^{[4
]}

Fensterl, Jaime ^{[5
]}

Gerds, Aaron T. ^{[6
]}

Caimi, Paolo F. ^{[2
]}

Tomlinson, Ben K. ^{[2
]}

Malek, Ehsan ^{[7
]}

Little, Jane A. ^{[8
]}

Rush, Mary Lynn ^{[9
]}

Bogati, Samjhana ^{[10
]}

Parsons, Eric ^{[9
]}

Kane, Donna ^{[11
]}

Carraway, Hetty E. ^{[4
]}

Nazha, Aziz ^{[6
]}

Hamilton, Betty K. ^{[6
]}

Sobecks, Ronald ^{[12
]}

Bevier, Barbara ^{[9
]}

Goebel, Christopher ^{[9
]}

Zimmerman, Cassie ^{[9
]}

Nielsen, Alek D. ^{[13
]}

Hirsch, Cassandra M. ^{[13
]}

Maciejewski, Jaroslaw P. ^{[13
]}

Kalaycio, Matt ^{[4
]}

deLima, Marcos ^{[14
]}

Jacobberger, James ^{[15
]}

Woost, Philip ^{[15
]}

Sekeres, Mikkael A. ^{[4
,16
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH USA

[2] Univ Hosp Case Med Ctr, Adult Hematol Malignancies & Stem Cell Transplant, Seidman Canc Ctr, Cleveland, OH USA

[3] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH USA

[4] Cleveland Clin, Taussig Canc Inst Leukemia Program, Cleveland, OH USA

[5] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH USA

[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[7] Univ Hosp Case Med Ctr, Cleveland, OH USA

[8] Case Western Reserve Univ Univ Hosp Seidman Canc, Div Hematol Oncol, Cleveland, OH USA

[9] Cleveland Clin Leukemia Program, Taussig Canc Inst, Cleveland, OH USA

[10] Cleveland Clin Taussig Canc Inst, Taussig Canc Inst Leukemia Program, Cleveland, OH USA

[11] Univ Hosp Cleveland, Seidman Canc Ctr, Cleveland, OH USA

[12] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Blood & Marrow Transplant Program, Cleveland, OH USA

[13] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH USA

[14] Univ Hosp, Adult Hematol Malignancies & Stem Cell Transplant, Seidman Canc Ctr, Cleveland, OH USA

[15] Case Western Reserve Univ, Cleveland, OH USA

[16] Cleveland Clin, Dept Hematol & Med Oncol, Leukemia Program, Cleveland, OH USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.4065.4065

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4065

引用

页数：5

共 50 条

[21] A Single Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia
Christian, Sonia
Patel, Pritesh
Esen, Aysenur
Khan, Irum
Sweiss, Karen
Ghanem, Fares
Sequeira, Christopher A.
Shergill, Ardaman
Quigley, John G.
BLOOD, 2017, 130
[22] Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Identifies Novel Biomarkers to Inform Mitoxantrone, Etoposide, and Cytarabine (MEC)-Based Combination Therapy in Refractory & Relapsed Acute Myeloid Leukemia (AML) Patients
Marcucci, Guido
Kumar, Ansu
Castro, Michael
Grover, Himanshu
Patil, Vivek
Alam, Aftab
Azam, Humera
Mohapatra, Subrat
Tyagi, Anuj
Kumari, Pallavi
Prasad, Samiksha Avinash
Nair, Prashant Ramachandran
Lunkad, Neelesh
Joseph, Vishwas
Poornachandra, G.
Chauhan, Jyoti
Basu, Sayani
Behura, Liptimayee
Ghosh, Adity
Husain, Zakir
Mandal, Rema
raman, Rahul K.
Patel, Sanjana
Mundkur, Nirjhar
Christie, James
Macpherson, Michele Dundas
Howard, Scott C.
BLOOD, 2021, 138
[23] A PEDIATRIC-ONCOLOGY-GROUP (POG) PHASE-II TRIAL OF MITOXANTRONE, ETOPOSIDE AND CYCLOSPORINE A (MEC) THERAPY FOR RELAPSED AND REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML)
DAHL, G
DUNUSSI, K
MOGUL, M
BROPHY, N
LOWE, K
GRIER, H
SIKIC, B
WEINSTEIN, H
ARCECI, R
BLOOD, 1993, 82 (10) : A195 - A195
[24] Outcome of etoposide and mitoxantrone for relapsed or refractory acute myeloid leukemia (RR-AML) in the modern era.
Bowman, Zelia Ramone Karema
Caddell, Ryan James
Kanate, Abraham Sebastian
Shillingburg, Alex
Shah, Nilay Arvind
Craig, Michael
Cumpston, Aaron
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[25] A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Christian, Sonia
Patel, Pritesh
Agrawal, Vaibhav
Griffin, Shawn
Cahill, Kirk
Khan, Irum
Sweiss, Karen
Shergill, Ardaman
Calip, Gregory Sampang
Stock, Wendy
Odenike, Olatoyosi
Konig, Heiko
Quigley, John G.
BLOOD, 2018, 132
[26] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study
Halpern, Anna B.
Buckley, Sarah A.
Othus, Megan
Huebner, Emily M.
Orlowski, Kaysey F.
Scott, Bart L.
Perdue, Andrea M.
Smith, Heather A.
Becker, Pamela S.
Hendrie, Paul C.
Cassone, Stephanie
Chen, Tara L.
Stirewalt, Derek L.
Estey, Elihu H.
Walter, Roland B.
BLOOD, 2016, 128 (22)
[27] A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia
Christian, Sonia
Arain, Saad
Patel, Pritesh
Khan, Irum
Calip, Gregory S.
Agrawal, Vaibhav
Sweiss, Karen
Griffin, Shawn
Cahill, Kirk
Konig, Heiko
Esen, Aysenur
Shergill, Ardaman
Odenike, Olatoyosi
Stock, Wendy
Quigley, John G.
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (08) : 937 - 943
[28] The Use of Clofarabine and Cytarabine Combination (CLARA) As Salvage Therapy for Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Leung, Anskar Y. H.
Tse, Eric
Liu, Herman S. Y.
Sim, Joycelyn
Kho, Bonnie C. S.
Yip, Sze-Fai
Lee, Harold K. K.
Kwong, Yok Lam
BLOOD, 2012, 120 (21)
[29] Relapsed and Refractory Acute Myeloid Leukemia (AML) Treated with AS1411 and Cytarabine: A Randomized Phase II Trial.
Stuart, Robert Kenneth
Acton, Gary
BLOOD, 2008, 112 (11) : 676 - 676
[30] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
Vey, N
Kantarjian, H
Beran, M
O'Brien, S
Cortes, J
Koller, C
Estey, E
INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) : 89 - 95

← 1 2 3 4 5 →